▷ Visible successes through delNS-based immunotherapy of equine sarcoids


10.12.2021 – 09:01

Bluesky Immunotherapies GmbH

Vienna (ots)

… open up new possibilities for cancer therapy in humans

Scientists from the Viennese biotechnology companyBlueSky Immunotherapies GmbH have used their viral vector platform delNS for the therapy of sarcoids in horses. Together with the oncological team at the University of Veterinary Medicine, Vienna headed by Dr. Sabine Brandt and the sarcoid specialist Edmund Hainisch have achieved sensational successes, which show further possibilities in the development of innovative and body-friendly cancer therapies in humans.

Sarcoids (see pictures in the appendix) are locally aggressive skin tumors. They are caused by the tumor antigens E6 and E7 of the bovine papillomavirus and have massive effects on the health and well-being of the animals concerned. Conventional therapies such as surgical removal or chemotherapy only have a limited effect and usually lead to the recurrence of the tumors.

As published in the last issue of PLoS ONE1, sarcoids treated with delNS / E6E7 could be completely and permanently eliminated. In addition, the strong, systemic, delNS-mediated immune stimulation also eliminated non-injected sarcoids. At the same time it could be shown that the papillomavirus, which causes the sarcoids, was eliminated.

The biotechnology companyBlueSky Immunotherapies GmbH has created a viral vector platform for the induction of interferon and expression of tumor antigens with its proprietary delNS technology. DelNS-based vectors have many properties for overcoming the immunosuppressive environment of tumors:

delNS vectors

  • induce a strong interferon response

(Interferon sindProteinswhich have an immune-stimulating, especially antiviral and antitumoral effect.)

  • activate T cells, dendritic cells and natural killer cells (essential cells for the immune system)
  • inhibit immunosuppressive cells

For the local treatment (direct injection into the tumors) of the horses, two types of delNS vectors were designed, manufactured and used. The clinical study was conducted over a period of three years on 29 horses with different treatment regimens. In 20 horse patients a visible and very strong regression of the sarcoids was achieved, 10 horse patients showed a 100% regression of the sarcoids (see pictures). “With the complete elimination of very aggressive and difficult to cure equine sarcoids, another important proof of the potential of our delNS platform has been achieved. We are therefore optimistic that we will also achieve significant healing successes in the currently ongoing clinical studies on women with tumors in the cervix or that these tumors will also be eliminated“, Explains Thomas Muster, CEO ofBlueSky Immunotherapies.

Summary of the results achieved in 2021:

  • Complete regression, ie complete regression of the tumor: 10 horses
  • Regression running: 10 horses
  • temporary regression: 3 horses
  • no regression: 6 horses

company

The focus of the companyBlueSky Immunotherapies GmbH is based on the use of our own platform technologies, which activate antiviral and antitumoral reactions. These properties will be used in the development of next generation immunotherapies against infectious diseases and cancer.

Press contact:

COMPANIES:
BlueSky Immunotherapies GmbH
1060 Vienna, Mariahilfer Strasse 101/1/21

UnivDoz Dr. DI Thomas Muster, CEO
www.bluesky-itx.com
[email protected]
Tel.: +43 664 1888028

PRESS & INQUIRIES:
Isolde M. Bergmann
[email protected]
Tel.: +43 699 12278607

Original content from: Bluesky Immunotherapies GmbH, transmitted by news aktuell


www.presseportal.de

Leave a Reply

Your email address will not be published.